October 25, 2017 06:08 PM EDTUpdated 07:27 PM
R&D

Am­gen buries the last big CETP drug, mark­ing the bit­ter end of a block­buster quest

John Carroll

Editor & Founder

Am­gen used its Q3 re­port to­day to quick­ly bury the last broad­ly fo­cused CETP drug in the clin­ic, clos­ing the fi­nal chap­ter in an R …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

WuXi com­pa­nies may sell units im­pact­ed by Biose­cure — re­port

Biotech's third quar­ter was rel­a­tive­ly bright — with a few caveats

EMA re­views hair loss prod­ucts fol­low­ing con­cerns about sui­ci­dal thoughts

Af­ter $14B ex­it, Karuna co-founder finds next bet; Ex-Re­genxbio CEO Ken Mills heads to Tag­works

Sanofi sells rare dis­ease drug En­jay­mo to Recor­dati for $825M up­front

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times